Obecabtagene Autoleucel
Obecabtagene autoleucel works by changing a person's T cells (a type of immune cell) so they can better recognize and kill cancer cells. T cells are collected from the patient's blood and in the lab a receptor is added to them that targets a protein called CD19 found on B cells. B cells are the immune cells that are cancerous in acute lymphoblastic leukemia. The modified T cells are grown in large numbers in the lab and then infused back into the patient. Once inside the body, obecabtagene autoleucel binds to the CD19 protein on cancer cells, helping the immune system kill the cancer cells. Obecabtagene autoleucel is a type of immunotherapy called CAR T-cell therapy.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Obecabtagene autoleucel is approved to treat adults with:
- B-cell acute lymphoblastic leukemia that has come back or did not get better during or after other treatment
Obecabtagene autoleucel is also being studied in the treatment of other conditions and other types of cancer.
More About Obecabtagene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
Clinical Trials Accepting Patients
Find Clinical Trials for Obecabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.